Patents may last 20 years on paper, but real market protection for a drug or biologic depends on how you combine patent terms, extensions, and US/EU regulatory exclusivity. This article explains the key building blocks in plain language for life sciences teams.

In life sciences and advanced materials sector, IP due diligence is more than a legal formality; it’s central to valuation, deal viability, and long-term competitiveness. This article outlines a practical roadmap for investors and growth-stage companies to assess IP assets, FTO, risk, and strategy with the rigor these transactions demand.